The "Parkinsonian Heart"

From novel vistas to advanced therapeutic approaches in Parkinson's disease

Francisco Fornai, Riccardo Ruffoli, Paola Soldani, Stefano Ruggieri, Antonio Paparelli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The present manuscript reviews novel data on the progressive involvement of different regions of the central nervous system as well as peripheral nerves in Parkinson's disease. Most of these regions are involved in the regulation of the autonomic nervous system, and their damage is concomitant with the specific loss of sympathetic cardiac axon terminals. This causes a cardiovascular dysfunction, which occurs solely in Parkinsonian patients. In order to specify the peculiarity of this cardiovascular alteration we coined the term "Parkinsonian Heart". This is characterized by a severe loss of the physiological noradrenergic innervation and a slight impairment of central autonomic control and it is often characterized by drug-induced morpho-functional alterations. In fact, the current dopamine substitution therapy could make worse such an already abnormal heart. For instance, structure-activity studies on dopamine substitutive drugs report that dopamine agonists belonging to the class of ergot derivatives may produce, with a high frequency, valvular fibrosis in Parkinsonian patients. These effects recently became a major issue and led to consider all ergot dopamine agonists as dangerous for the treatment of Parkinson's disease. In the present review we re-describe the effects of dopamine agonist within the specific context of the Parkinsonian heart. In line with this, additional factors need to be considered: 1-The lack of noradrenergic innervation which might play a significant role in the fibrogenic mechanism. 2-The ergot structure per se, which is not sufficient, but it is rather the ability to act as agonist at 5HT2B or alpha-noradrenergic receptors to determine the fibrotic reaction. Therefore, we suggest that binding to these receptor subtypes, joined with the lack of endogenous noradrenergic innervation, might synergize to produce the cardiac fibrosis.

Original languageEnglish
Pages (from-to)2421-2428
Number of pages8
JournalCurrent Medicinal Chemistry
Volume14
Issue number23
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Dopamine Agonists
Parkinson Disease
Neurology
Fibrosis
Dopamine Agents
Manuscripts
Autonomic Nervous System
Presynaptic Terminals
Peripheral Nerves
Dopamine
Substitution reactions
Therapeutics
Central Nervous System
Derivatives
Pharmaceutical Preparations

Keywords

  • Cardiac fibrosis
  • Dopamine agonists
  • Ergot derivatives
  • Multiple system atrophy
  • Noradrenaline
  • Orthostatic hypotension
  • Parkinson's disease
  • Sympathetic nervous system

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

The "Parkinsonian Heart" : From novel vistas to advanced therapeutic approaches in Parkinson's disease. / Fornai, Francisco; Ruffoli, Riccardo; Soldani, Paola; Ruggieri, Stefano; Paparelli, Antonio.

In: Current Medicinal Chemistry, Vol. 14, No. 23, 10.2007, p. 2421-2428.

Research output: Contribution to journalArticle

Fornai, Francisco ; Ruffoli, Riccardo ; Soldani, Paola ; Ruggieri, Stefano ; Paparelli, Antonio. / The "Parkinsonian Heart" : From novel vistas to advanced therapeutic approaches in Parkinson's disease. In: Current Medicinal Chemistry. 2007 ; Vol. 14, No. 23. pp. 2421-2428.
@article{474ecfa6725b4897bb36cbd888d2665b,
title = "The {"}Parkinsonian Heart{"}: From novel vistas to advanced therapeutic approaches in Parkinson's disease",
abstract = "The present manuscript reviews novel data on the progressive involvement of different regions of the central nervous system as well as peripheral nerves in Parkinson's disease. Most of these regions are involved in the regulation of the autonomic nervous system, and their damage is concomitant with the specific loss of sympathetic cardiac axon terminals. This causes a cardiovascular dysfunction, which occurs solely in Parkinsonian patients. In order to specify the peculiarity of this cardiovascular alteration we coined the term {"}Parkinsonian Heart{"}. This is characterized by a severe loss of the physiological noradrenergic innervation and a slight impairment of central autonomic control and it is often characterized by drug-induced morpho-functional alterations. In fact, the current dopamine substitution therapy could make worse such an already abnormal heart. For instance, structure-activity studies on dopamine substitutive drugs report that dopamine agonists belonging to the class of ergot derivatives may produce, with a high frequency, valvular fibrosis in Parkinsonian patients. These effects recently became a major issue and led to consider all ergot dopamine agonists as dangerous for the treatment of Parkinson's disease. In the present review we re-describe the effects of dopamine agonist within the specific context of the Parkinsonian heart. In line with this, additional factors need to be considered: 1-The lack of noradrenergic innervation which might play a significant role in the fibrogenic mechanism. 2-The ergot structure per se, which is not sufficient, but it is rather the ability to act as agonist at 5HT2B or alpha-noradrenergic receptors to determine the fibrotic reaction. Therefore, we suggest that binding to these receptor subtypes, joined with the lack of endogenous noradrenergic innervation, might synergize to produce the cardiac fibrosis.",
keywords = "Cardiac fibrosis, Dopamine agonists, Ergot derivatives, Multiple system atrophy, Noradrenaline, Orthostatic hypotension, Parkinson's disease, Sympathetic nervous system",
author = "Francisco Fornai and Riccardo Ruffoli and Paola Soldani and Stefano Ruggieri and Antonio Paparelli",
year = "2007",
month = "10",
doi = "10.2174/092986707782023631",
language = "English",
volume = "14",
pages = "2421--2428",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "23",

}

TY - JOUR

T1 - The "Parkinsonian Heart"

T2 - From novel vistas to advanced therapeutic approaches in Parkinson's disease

AU - Fornai, Francisco

AU - Ruffoli, Riccardo

AU - Soldani, Paola

AU - Ruggieri, Stefano

AU - Paparelli, Antonio

PY - 2007/10

Y1 - 2007/10

N2 - The present manuscript reviews novel data on the progressive involvement of different regions of the central nervous system as well as peripheral nerves in Parkinson's disease. Most of these regions are involved in the regulation of the autonomic nervous system, and their damage is concomitant with the specific loss of sympathetic cardiac axon terminals. This causes a cardiovascular dysfunction, which occurs solely in Parkinsonian patients. In order to specify the peculiarity of this cardiovascular alteration we coined the term "Parkinsonian Heart". This is characterized by a severe loss of the physiological noradrenergic innervation and a slight impairment of central autonomic control and it is often characterized by drug-induced morpho-functional alterations. In fact, the current dopamine substitution therapy could make worse such an already abnormal heart. For instance, structure-activity studies on dopamine substitutive drugs report that dopamine agonists belonging to the class of ergot derivatives may produce, with a high frequency, valvular fibrosis in Parkinsonian patients. These effects recently became a major issue and led to consider all ergot dopamine agonists as dangerous for the treatment of Parkinson's disease. In the present review we re-describe the effects of dopamine agonist within the specific context of the Parkinsonian heart. In line with this, additional factors need to be considered: 1-The lack of noradrenergic innervation which might play a significant role in the fibrogenic mechanism. 2-The ergot structure per se, which is not sufficient, but it is rather the ability to act as agonist at 5HT2B or alpha-noradrenergic receptors to determine the fibrotic reaction. Therefore, we suggest that binding to these receptor subtypes, joined with the lack of endogenous noradrenergic innervation, might synergize to produce the cardiac fibrosis.

AB - The present manuscript reviews novel data on the progressive involvement of different regions of the central nervous system as well as peripheral nerves in Parkinson's disease. Most of these regions are involved in the regulation of the autonomic nervous system, and their damage is concomitant with the specific loss of sympathetic cardiac axon terminals. This causes a cardiovascular dysfunction, which occurs solely in Parkinsonian patients. In order to specify the peculiarity of this cardiovascular alteration we coined the term "Parkinsonian Heart". This is characterized by a severe loss of the physiological noradrenergic innervation and a slight impairment of central autonomic control and it is often characterized by drug-induced morpho-functional alterations. In fact, the current dopamine substitution therapy could make worse such an already abnormal heart. For instance, structure-activity studies on dopamine substitutive drugs report that dopamine agonists belonging to the class of ergot derivatives may produce, with a high frequency, valvular fibrosis in Parkinsonian patients. These effects recently became a major issue and led to consider all ergot dopamine agonists as dangerous for the treatment of Parkinson's disease. In the present review we re-describe the effects of dopamine agonist within the specific context of the Parkinsonian heart. In line with this, additional factors need to be considered: 1-The lack of noradrenergic innervation which might play a significant role in the fibrogenic mechanism. 2-The ergot structure per se, which is not sufficient, but it is rather the ability to act as agonist at 5HT2B or alpha-noradrenergic receptors to determine the fibrotic reaction. Therefore, we suggest that binding to these receptor subtypes, joined with the lack of endogenous noradrenergic innervation, might synergize to produce the cardiac fibrosis.

KW - Cardiac fibrosis

KW - Dopamine agonists

KW - Ergot derivatives

KW - Multiple system atrophy

KW - Noradrenaline

KW - Orthostatic hypotension

KW - Parkinson's disease

KW - Sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=35449006737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35449006737&partnerID=8YFLogxK

U2 - 10.2174/092986707782023631

DO - 10.2174/092986707782023631

M3 - Article

VL - 14

SP - 2421

EP - 2428

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 23

ER -